Let me take that kind of in two parts. Let me speak about actually in 2024 from a releasing perspective of existing space. We had actually only one very small tenant leave us. So we had a, you know, very high nineties percent renewal rate for our tenancy. We were already working not just on 2025, possible expirations, but also 2026. So as you could see by our results that we displayed, you know, for the fourth quarter, particularly with the, you know, post-acute medical transaction as well as actually some others that we're working on now, we are very proactive about managing the existing portfolio to push out lease expirations. We think there's a lot of benefit to our stockholders and, of course, creates that durable, predictable income train. As it relates to, we do think we've had an improvement in credit metrics. I think, you know, it's reflective of the healthcare industry doing better each and every quarter and, frankly, every year. You know, since coming out of COVID and particularly really over the last, I would say, 24 months, managing labor issues, managing supply issues, you know, for their businesses. And I think that's really what you see because, as mentioned, what you would note, we only have three tenants in two properties under one times coverage. And I'll just mention of those three tenants, one of those tenants is a very high investment-grade rated tenant. And I will also mention to you that all three of those tenants are current on rent. So we feel very good about the portfolio. In terms of sort of, you know, where our focus is with, if you're asking, I think, really about watch list. And we've often said, hey, everything in our portfolio is on our watch list because we're watching all the time. You know, we're very focused on, I would tell you, selling the Stoughton asset. It's, you know, admittedly a drag. And we've hired a nationally recognized broker, and they are deep into the process, sale process, and we're pleased with the feedback that we're getting. You know, I think, you know, the push that the team hears from me every day is, I would like it sold last week. Or at least last week. So that's a big focus of ours. I think we've actually had probably a reduction to a certain degree in our most high monitoring as we've gotten, of course, through, I mean, Stoughton's resolve in the sense that we own the only asset, and it's obviously vacant at this time. We've gotten through Genesis Care, as we had mentioned. So I would tell you from a high monitoring perspective, we've had things kind of improve what I think is dramatically.